Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, ALR was found to enhance both the proliferation and osteogenic differentiation of mouse bone marrow mesenchymal stem cells, potentially through specific signaling pathways.

This study observed that thymol from Origanum marjoram essential oil significantly promoted hair regrowth and reduced inflammation in cyclophosphamide-induced alopecia in rabbits, with effects that were comparable to or exceeded those of betamethasone, highlighting its potential as a safer treatment alternative.

This study reports that a specific transporter protein in Staphylococcus hominis is responsible for transporting a malodour precursor, thereby playing a key role in human body odor production.

This abstract reviews the use of low dose oral minoxidil as a monotherapy for hair loss and reports no new clinical data.

This study found that Zizyphus jujuba fruit aqueous extract may reduce nephrotoxicity caused by ibuprofen in rats by lowering serum urea and creatinine and improving kidney antioxidant enzyme activities.

This study found that β-sitosterol, a brain-penetrable phytosterol, reduced melanoma cell growth and brain metastasis formation by interfering with mitochondrial respiration, suggesting its potential as an adjuvant therapy to BRAF inhibitors for patients with melanoma brain metastases.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This dataset provides supplemental material for a study on long-term particulate matter exposure and androgenetic alopecia risk, including additional exposure data and sensitivity analyses, but reports no new clinical results.

This case study describes a 54-year-old man with an E600A mutation in the NOD-2 gene associated with Blau syndrome, who presented with skin involvement, differing from typical cases, and initially responded to colchicine treatment.

This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.

This study employed multiple linear regressions to analyze hydantoin analogues and produced a model with strong predictive abilities for designing new androgen receptor modulators.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

In this randomized clinical trial, minoxidil at 5 mg was not found to be superior to 2.5 mg for treating male androgenetic alopecia over 24 weeks, though the higher dose more frequently caused side effects like pre-tibial edema and dizziness.

This review highlights the dual nature of Abrus precatorius as both a traditional medicine and a toxin, emphasizing its rich phytochemical profile and potential therapeutic applications, while noting the need for rigorous quality control and clinical trials to ensure safety and efficacy.

This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This report observed that a male developed erythema multiforme linked to both topical and oral minoxidil use for androgenetic alopecia, supported by eruption recurrence with reapplication.

In this case study, treatment with methylene blue successfully improved blood pressure in a patient with refractory vasodilatory shock due to massive minoxidil ingestion, highlighting its potential as an adjunctive therapy.

Media coverage increased public interest in oral minoxidil for hair loss but may also spread misinformation.

This study found that combining ablative fractional CO2 laser treatment with topical minoxidil significantly improved frontal hairline regrowth and patient satisfaction in men with androgenetic alopecia compared to using minoxidil alone, without serious adverse effects.

This article discusses the role of external beam radiotherapy as a primary treatment method for cancer and reports no new clinical findings.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

This study found that topical Ivermectin 0.1% was the most effective treatment for rabbit mange among the tested options, achieving 100% survival, no persistent skin scales, and significant body weight changes, while topical cebacil gel resulted in 100% mortality and should not be used.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.

This study found that an optimized microemulsion for minoxidil with high solubility, permeation flux, and skin deposition can be achieved with specific low and high levels of certain surfactants and co-solvents.

This systematic review reported objective clinical improvement with low-dose oral minoxidil in up to 100% of patients with androgenetic alopecia and up to 82.4% with alopecia areata.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This case report describes a 5-year-old boy who developed generalized hypertrichosis after using 3% topical minoxidil for alopecia areata, which resolved six months after discontinuation.